Osteologix/Servier. I keep a running log of deals and it clocked in as the weakest P2/P3 deal. Upfront being undisclosed tells you something.
Securing an SPA was a good step and that should help as far as raising equity financing to run a pivotal study. But I still think they'll have a lot of trouble securing FDA approval due to catastrophic risk from hyper allergic reactions in europe. The FDA bar for risk in a well served market is low. The comparable is Indevus and their injectable testosterone that's been delayed for several years due to the european experience of 1 in a million coughing fits which self resolve. Death vs coughing. You can worry about that in 3-4 years after they file for approval.
News 
Market Data 
Discover 
